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ABSTRACT
Objectives. To evaluate the spectrum of neurological symptoms in patients with COVID-19 during the first 14 days of hospita-
lisation and its association with in-hospital mortality.
Material and methods. We included 200 patients with RT-PCR-confirmed COVID-19 admitted to University Hospital in Krakow, 
Poland. In 164 patients, a detailed questionnaire concerning neurological symptoms and signs was performed prospectively 
within 14 days of hospitalisation. In the remaining 36 patients, such questionnaires were completed retrospectively based on 
daily observations in the Department of Neurology.
Results. During hospitalisation, 169 patients (84.5%) experienced neurological symptoms; the most common were: fatigue 
(62.5%), decreased mood (45.5%), myalgia (43.5%), and muscle weakness (42.5%). Patients who died during hospitalisation 
compared to the remainder were older (79 [70.5–88.5] vs. 63.5 [51–77] years, p = 0.001), and more often had decreased level of 
consciousness (50.0% vs. 9.3%, p < 0.001), delirium (33.3% vs. 4.4%, p < 0.001), arterial hypotension (50.0% vs. 19.6%, p = 0.005) 
or stroke during (18.8% vs. 3.3%, p = 0.026) or before hospitalisation (50.0% vs. 7.1, p < 0.001), whereas those who survived more 
often suffered from headache (42.1% vs. 0%, p = 0.012) or decreased mood (51.7% vs. 0%, p = 0.003).
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Conclusions. Most hospitalised patients with COVID-19 experience neurological symptoms. Decreased level of consciousness, 
delirium, arterial hypotension, and stroke during or before hospitalisation increase the risk of in-hospital mortality.
Key words: COVID-19, Sars-Cov-2 infection, Neuro-COVID-19, neurological symptoms, in-hospital mortality
(Neurol Neurochir Pol 2021; 55 (3): 315–321)
Introduction
Poland is among the eight worst-hit countries in Europe 
in terms of the prevalence of novel coronavirus causing Coro-
navirus Disease 2019 (COVID-19), with more than two and 
a half million affected people, and nearly 60,000 deaths, as of 
11 April, 2021 [1].
Numerous infectious diseases with pandemic and epi-
demic potential can cause neurological symptoms in their 
course [2]. With an increasing number of patients, neuro-
logical manifestations of severe acute respiratory syndrome 
coronavirus 2 (SARS-Cov-2) infection also became apparent, 
with the first study from Wuhan showing that this could 
apply to one in every three cases [3]. Later studies revealed 
that the frequency of neurological symptoms might be even 
higher, ranging from 57.4% in hospitalised patients with 
COVID-19 in Spain [4] to 73.0% in a mixed cohort of outpa-
tient and hospitalised patients in a single centre in the state 
of Washington, USA [5]. However, most of these studies had 
a retrospective design which consequently might result in 
underestimation of the frequency of neurological manifes-
tations in SARS-Cov-2 infection.
Recently, two prospective studies on neurological symp-
toms in COVID-19 patients were performed, in which 
neurological consultation was used to identify neurological 
manifestations [6, 7]. Fleischer et al. showed that nearly 
60% of 102 patients infected with the SARS-Cov-2 virus had 
non-specific neurological involvement with general weakness, 
cognitive decline or delirium [6]. In another study, the most 
common neurological complaints in a cohort of 873 Iranian 
patients were: smell and taste dysfunction, myalgia, headache, 
and dizziness [7]. 
Therefore, due to discrepancy in the frequency of neurolog-
ical symptoms among patients infected with the SARS-Cov-2 
virus, we aimed to evaluate the frequency and spectrum of 
neurological symptoms in COVID-19 patients during the first 
14 days of hospitalisation, and to seek any possible association 
with in-hospital mortality.
Material and methods
We recruited patients admitted between March and Sep-
tember 2020 to four different departments of the University 
Hospital in Krakow — Neurology, Metabolic Diseases and 
Diabetology, Internal Medicine, and Otorhinolaryngology 
— which during the pandemic was transformed into the 
main centre for patients with the SARS-Cov-2 infection in 
the region of Lesser Poland. All patients had the diagnosis of 
COVID-19 confirmed by the detection of SARS-Cov-2 RNA 
by real-time reverse transcription-polymerase chain reaction 
(RT-PCR) from a nasopharyngeal swab.
Causes of hospital admission, and therefore inclusion cri-
teria for participation in the study, were as follows: dyspnoea, 
low blood saturation (≤ 92%), chronic disease which had to be 
treated in hospital, or lack of possibility of isolation. Excluded 
were: patients younger than 18 years and those who needed 
mechanical ventilation on hospital admission.
In most patients (n = 164), a detailed questionnaire con-
cerning the presence of 12 neurological symptoms (headache, 
dizziness, decreased mood, memory or concentration diffi-
culties, fatigue, visual disturbances, anosmia, ageusia, muscle 
weakness, myalgia, paresthesia, and increased sweating) and 
eight neurological signs (decreased level of consciousness, 
delirium, ataxia, seizure, stroke/TIA, autonomic disturbanc-
es such as diarrhoea, arterial hypotension < 90/60mmHg or 
tachycardia > 100/min) was performed prospectively within 
14 days of hospitalisation by both patients and physicians. In 
the remaining 36 patients, such questionnaires were completed 
retrospectively on the basis of detailed daily clinical records in 
the computerised hospital system in the Department of Neu-
rology. We additionally collected data concerning respiratory 
and gastrointestinal symptoms of COVID-19, comorbidities, 
and in-hospital mortality.
Written or verbal — in the presence of two witnesses — 
informed medical consent was obtained from each patient fol-
lowed prospectively. This study was conducted in accordance 
with the Declaration of Helsinki and approved by the Bioethics 
Committee of the District Medical Council in Krakow (opin-
ion number 143/KBL/OIL/2020).
We presented categorical data as counts and percentages 
and continuous data as mean and standard deviation (SD), 
median and interquartile range (IQR). We tested continu-
ous variables for normality with the Shapiro-Wilk test and 
compared, as appropriate, by the Student’s t-test or by the 
Mann-Whitney U test. A p-value of 0.05 (two-sided) was 
considered statistically significant. We performed all sta-
tistical analyses with STATISTICA version 13 (Statsoft Inc, 
Tulsa, OK, USA).
The data confirming the results of this study is available 
from the corresponding author upon reasonable request.
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Results
This study included 200 consecutive patients hospitalised 
in four departments of the University Hospital in Krakow 
– Neurology (29.0%, n = 58), Metabolic Diseases and Dia-
betology (54.5%, n = 109), Internal Medicine (10%, n = 20), 
and Otorhinolaryngology (6.5%, n = 13). Patients were ad-
mitted from home (62.5%, n = 125), another hospital (27.5%, 
n = 55), nursing home (9.0%, n = 18), or institutional isolation 
(1.0%, n = 2).
Median patient age during hospitalisation was 65.0 (in-
terquartile range, IQR 52.0-78.5) years and there were 56.0% 
females (n = 112). Median time from first COVID-19 symp-
toms to hospital admission was 5 (IQR 3-7) days, whereas 
the median time from first positive nasopharyngeal swab 
test to the onset of hospitalisation was 1 (IQR 1-3) day. In 
128 patients (64.0%), the following comorbidities were not-
ed: hypertension (57.5%, n = 115), diabetes mellitus (26.5%, 
n = 53), ischaemic heart disease (17.5%, n = 35), obesity 
(16.5%, n = 33), chronic renal disease (4.5%, n = 9), cancer 
(4.5%, n = 9), and chronic obstructive pulmonary disease or 
asthma (4.0%, n = 8). Eleven (5.5%) and 19 (14.5%) patients 
had a history of cancer or stroke, respectively. There were six 
(3.0%) current and 29 (14.5%) past smokers.
First manifestations of SARS-Cov-2 infection were as fol-
lows: cough (57.5%, n = 115), fever (body temperature ≥ 38ºC; 
52.0%, n = 104), dyspnoea (48.5%, n = 97), loss of appetite 
(27.5%, n = 55), diarrhoea (24.0%, n = 48), abdominal pain 
(18.5%, n = 37) and sore throat (12.5%, n = 25). At day 14 since 
the onset of hospitalisation, 22 (11%) patients were receiving 
oxygen therapy and seven (3.5%) were mechanically ventilated. 
There were 16 (8.0%) deaths at a median 12.5 (IQR 8.5–28.5) 
days of hospitalisation.
During a median 14 (IQR 8-22) days of hospitalisation, 
169 patients (84.5%) experienced some form of neurological 
symptom or sign. In 20 patients (10.0%) neurological symp-
toms were the first manifestation of SARS-Cov-2 infection 
accompanying respiratory or gastrointestinal symptoms. 
The most common neurological symptoms were: fatigue 
(62.5%), decreased mood (45.5%), myalgia (43.5%), muscle 
weakness (42.5%) and headache (37.0%) (Tab. 1). Most neu-
rological symptoms had an onset within the first three days 
of hospitalisation, whereas paresthesia or arterial hypotension 
< 90/60mmHg occurred later in the disease course (median 
6 days, IQR 1-11 or 7.5 days, IQR 3-13, respectively; Tab. 1).
Patients who died during hospitalisation compared to the 
remainder were older, and more often had a decreased level of 
consciousness, delirium, arterial hypotension or stroke during 
or before hospitalisation, whereas those who survived more 
often suffered from headache or decreased mood (Tab. 2). 
When the analysis was restricted to patients followed pro-
spectively, those who died during hospitalisation compared to 
survivors were older (83 [76–87] vs. 63 [50–77] years, p < 0.001) 
and more often had a decreased level of consciousness 
(44.4% vs. 7.8%, p = 0.006), delirium (50.0% vs. 3.9%, 
p < 0.001), or a history of stroke (44.4% vs. 5.8%, p = 0.002) 
(Tab. 3). Among patients recruited prospectively, those who 
survived compared to the remainder more often complained 
of decreased mood (54.7% vs. 0.0%, p = 0.021) (Tab. 3).
Discussion
Our study showed that different neurological symptoms 
exerted a diverse association with in-hospital mortality in 
patients with COVID-19. Some of them, possible to assess re-
gardless of patient cooperation such as delirium or decreased 
level of consciousness, were linked to the risk of death during 
hospitalisation. This observation was in line with a previous 
study in which a short and simple scale for mortality risk 
was validated in a cohort of more than 20,000 patients with 
COVID-19 and which consisted of eight parameters with 
a level of consciousness among others [8]. A recent Italian 
study also confirmed that patients with COVID-19 and 
delirium on admission had a nearly two-fold higher risk of 
in-hospital mortality compared to those without delirium 
[9]. In another study, consisting of a retrospective analysis 
of electronic medical records of 307 COVID-19 patients in 
Turkey, it was shown that altered mental status was the most 
common neurological manifestation and associated with 
a higher mortality rate [10].
On the other hand, in our study some symptoms which 
could be evaluated only in those patients who were able to fill 
out the questionnaire, such as headache or decreased mood, 
increased the chance of survival. Our results were similar to 
the findings of a prospective study of nearly 900 patients with 
SARS-Cov-2 infection where the presence of headache was 
a protective factor against death due to COVID-19 [7]. The 
frequency of headache in previous studies has been reported 
as between 7% and 75%, with higher percentages in European 
populations than in Chinese cohorts [11]. 
We hypothesise that the protective role of headache and 
decreased mood in terms of mortality due to COVID-19 could 
be — at least partially — explained by the inflammatory pro-
cess occurring in the body of these patients and leading to 
virus elimination [12]. Indeed, in a recent Chinese study of 
77 patients with COVID-19, those who suffered from anxiety 
had higher serum levels of IL-6 and IL-10, whereas those 
with depression had higher CD8+ T-cell count and lower 
CD4+/CD8+ ratio compared to the remainder [13]. What is 
more, as it was shown in a large American cohort of nearly 
4,000 patients with prior SARS-Cov-2 infection, the sever-
ity of COVID-19 symptoms and the presence of headache 
increased the risk of subsequent major depression by 2.6 and 
1.3-fold, respectively [14]. Recently, so-called lesser neuro-
logical symptoms such as fatigue, inability to concentrate, 
myalgia, and headache, were found to have the potential to 
become chronic and result in the syndrome recently labelled 
as Long Covid [15].
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Onset of neurological 
symptom or sign  
(days of hospitalisa-
tion, median and IQR)
Duration of neurolo-
gical symptom or sign 
(days of hospitalisa-
tion, median and IQR)
Number of patients 
who declared to have 
neurological symptom 









2 (1–5) 2 (1–3) 11 (5.5)
Dizziness No 
Yes 




3 (1–7) 2 (1–2) 8 (4.0)
Decreased mood No 
Yes 













1 (1–8) 3 (2–5) 4 (2.0)
Fatigue No 
Yes 




1 (1–4) 5 (2–8) 10 (5.0)
Visual disturbances No 
Yes 




1 (1–10) 2 (1–3) 1 (0.5)
Anosmia No 
Yes 




1 (1–1) 4 (2–9) 7 (3.5)
Ageusia No 
Yes 




1 (1–4) 4 (2–8) 5 (2.5)
Muscle weakness No 
Yes 




1 (1–6) 4 (1–8.5) 17 (8.5)
Myalgia No 
Yes 




1 (1–6) 2 (1–5) 10 (5.0)
Paresthesia No 
Yes 




6 (1–11) 1 (1–4) 3 (1.5)
Increased sweating No 
Yes 




3 (1–8) 2 (1–6) 7 (3.5)
Neurological signs








1 (1–4) 5 (3–15) 1 (0.5)
Delirium No 
Yes 




3 (1–7) 7 (4–9) 3 (1.5)
Diarrhoea No 
Yes 




3 (1–6) 2 (1–3) 8 (4.0)
Arterial hypoten-
sion < 90/60 mmHg
No 
Yes 













3.5 (1–9) 2 (1–3) 0 (0.0)
Ataxia No 
Yes 




1.5 (1–8) 1 (1–1) 1 (0.5)
Seizure No 
Yes 




1 (1–1) 0.5 (0–1) 0 (0.0)
Stroke or TIA No 
Yes 




5 (1–11) 1 (1–1) 0 (0.0)
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Table 2. Comparison of patients with COVID-19 who survived or died during hospitalisation 
Patients who survived during 
hospitalisation 
n = 184





Female sex 103 (55.6) 9 (56.2) 0.982
Age 63.5 (51–77) 79 (70.5–88.5) 0.001
First COVID-19 symptoms
Fever 94 (51.2) 10 (62.5) 0.381
Cough 107 (58.2) 8 (50.0) 0.527
Sore throat 23 (12.5) 2 (12.5) 1.000
Loss of appetite 52 (28.3) 3 (18.8) 0.413
Dyspnoea 88 (47.8) 10 (62.5) 0.260
Diarrhoea 44 (23.9) 4 (25.0) 0.922
Abdominal pain 35 (19.0) 2 (12.5) 0.519
Neurological symptoms and signs
Headache 74 (42.1) 0 (0.0) 0.012
Dizziness 49 (27.8) 0 (0.0) 0.065
Decreased mood 91 (51.7) 0 (0.0) 0.003
Memory or concentration difficulties 31 (17.6) 3 (30.0) 0.324
Fatigue 122 (69.3) 3 (33.3) 0.060
Visual disturbances 11 (6.3) 0 (0.0) 0.439
Decreased level of consciousness 17 (9.3) 8 (50.0) < 0.001
Delirium 8 (4.4) 5 (33.3) < 0.001
Seizure 0 (0.0) 1 (6.2) 0.080
Ataxia 4 (2.2) 0 (0.0) 1.000
Stroke/TIA 6 (3.3) 3 (18.8) 0.026
Anosmia 42 (23.9) 1 (11.1) 0.687
Ageusia 53 (30.1) 1 (11.1) 0.287
Muscle weakness 80 (44.9) 5 (55.6) 0.532
Myalgia 69 (39.2) 4 (44.4) 0.741
Paresthesia 44 (35.0) 2 (22.2) 1.000
Diarrhoea 59 (32.1) 3 (20.0) 0.400
Increased sweating 68 (38.6) 3 (27.3) 0.538
Arterial hypotension (< 90/60mmHg) 36 (19.6) 8 (50.0) 0.005
Tachycardia (> 100/min) 50 (27.2) 6 (37.5) 0.378
Any neurological symptom or sign 158 (85.9) 11 (68.8) 0.069
Comorbidities
Hypertension 106 (62.4) 9 (64.3) 0.885
Ischaemic heart disease 31 (18.3) 4 (28.9) 0.312
Diabetes mellitus 47 (27.8) 6 (42.9) 0.233
History of stroke 12 (7.1) 7 (50.0) < 0.001
Asthma/Chronic Obstructive Pulmonary Disease 8 (4.7) 0 (0.0) 1.000
Cancer 19 (11.2) 1 (7.1) 1.000
— No cancer 
— Current cancer 








Chronic renal disease 7 (4.1) 2 (14.3) 0.143
Obesity 30 (17.8) 3 (21.4) 0.720
Smoking 33 (19.9) 2 (14.3) 1.000
— No smoking 
— Current smoking 
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Table 3. Comparison of patients with COVID-19 recruited prospectively who survived or died during hospitalisation 
Patients who survived during 
hospitalisation 
n = 155





Female sex 94 (60.7) 4 (4.4) 0.485
Age 63 (50–77) 83 (76–87) < 0.001
First COVID-19 symptoms
Fever 77 (49.7) 4 (44.4) 1.000
Cough 88 (56.8) 2 (22.2) 0.080
Sore throat 118 (11.6) 1 (11.1) 1.000
Loss of appetite 44 (28.4) 2 (22.2) 1.000
Dyspnoea 67 (43.2) 6 (66.7) 0.169
Diarrhoea 37 (23.9) 0 (0.0) 0.211
Abdominal pain 29 (18.7) 0 (0.0) 0.363
Neurological symptoms and signs
Headache 65 (43.9) 0 (0.0) 0.073
Dizziness 43 (29.1) 0 (0.0) 0.322
Decreased mood 81 (54.7) 0 (0.0) 0.021
Memory or concentration difficulties 26 (17.6) 3 (50.0) 0.081
Fatigue 110 (74.3) 2 (40.0) 0.112
Visual disturbances 11 (7.4) 0 (0.0) 1.000
Decreased level of consciousness 12 (7.8) 4 (44.4) 0.006
Delirium 6 (3.9) 4 (50.0) < 0.001
Seizure 0 (0.0) 0 (0.0) 1.000
Ataxia 1 (0.7) 0 (0.0) 1.000
Stroke/TIA 4 (2.6) 1 (11.1) 0.248
Anosmia 39 (26.4) 1 (20.0) 1.000
Ageusia 52 (35.1) 1 (20.0) 0.659
Muscle weakness 68 (45.3) 2 (40.0) 1.000
Myalgia 59 (39.9) 2 (40.0) 1.000
Paresthesia 27 (25.0) 1 (20.0) 1.000
Diarrhoea 52 (33.6) 0 (0.0) 0.057
Increased sweating 65 (43.9) 2 (40.0) 1.000
Arterial hypotension ( < 90/60mmHg) 35 (22.6) 4 (44.4) 0.218
Tachycardia ( > 100/min) 45 (29.1) 3 (33.3) 0.721
Any neurological symptom or sign 135 (87.1) 6 (66.7) 0.115
Comorbidities
Hypertension 95 (61.3) 7 (77.8) 0.321
Ischaemic heart disease 27 (17.4) 3 (33.3) 0.213
Diabetes mellitus 43 (27.7) 3 (3.3) 0.711
History of stroke 9 (5.8) 4 (44.4) 0.002
Asthma/Chronic Obstructive Pulmonary Disease 8 (5.2) 0 (0.0) 1.000
Cancer 19 (11.2) 1 (7.1) 1.000
— No cancer 
— Current cancer 








Chronic renal disease 7 (4.5) 2 (22.2) 0.079
Obesity 29 (18.7) 1 (11.1) 1.000
Smoking 28 (18.4) 2 (22.2) 0.675
— No smoking 
— Current smoking 
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We also revealed that patients with COVID-19 with pre-
vious stroke and older age had a greater risk of in-hospital 
mortality. Stroke during COVID-19 was also associated with 
increased in-hospital mortality in the whole group but not in 
the prospective cohort, probably due to severe neurological 
deficit which prevented these patients from filling out the 
questionnaire. Previous research has shown that chronic 
neurological comorbidity increases the risk of in-hospital 
mortality [16, 17]. A recent meta-analysis of 18 studies, mostly 
of retrospective design, revealed that the mortality rate in 
COVID-19 patients with concomitant stroke was concerning 
and, especially in relation to ischaemic stroke, higher than 
would be expected due to stroke itself [18]. 
Several possible aetiologies of stroke in COVID-19 pa-
tients include hypercoagulable state, cardioembolism, and 
direct viral-induced pathology of the endothelium, whereas 
increased mortality rate of stroke patients could be, at least 
partly, explained by limited hospital resources [19]. A pre-
vious meta-analysis of 109 articles showed that the risk of 
mortality was higher in older patients, which was similar 
to the results of our study, but additionally pointed to male 
gender, dyspnoea, diabetes mellitus, and hypertension as 
risk factors for death [20]. We were unable to replicate these 
findings, probably due to the small number of patients who 
died during our study.
Our study showed that neurological symptoms were found 
in 84.5% of patients hospitalised due to COVID-19. This pro-
portion was quite high compared to the previous retrospective 
studies from Wuhan [3] and Washington state [5]. However, 
in contrast to previous research, 82% of our patients were fol-
lowed-up prospectively during hospitalisation with a detailed 
clinical questionnaire. Therefore, physicians should proactively 
ask patients with COVID-19 about neurological symptoms in 
the course of hospitalisation. Additionally, most neurological 
symptoms occurred at the beginning of hospitalisation which 
was similar to the experience of Chinese authors [21].
The most common neurological symptoms in our cohort 
were fatigue, decreased mood, myalgia, muscle weakness and 
headache. A recent review of the literature showed that the 
majority of COVID-19 patients complained of non-specific 
neurological manifestations early in the disease course, with 
headache, dizziness, excessive tiredness, myalgia, anosmia/ 
/hyposmia, and ageusia/dysgeusia being the most common 
[22]. Even in a detailed study of 53 patients encompassing 
data of cerebrospinal fluid and radiological analysis together 
with electroencephalography, the most common neurologi-
cal features of hospitalised COVID-19 patients, apart from 
abnormalities in neurological examination, were cognitive 
impairment, hyposmia, headache, general muscle weakness 
and pain [23]. These symptoms usually occurred during the 
acute phase of COVID-19 infection, following an incubation 
period of 5-6 days, but some of them, especially fatigue and 
cognitive impairment, became chronic during the post-
infectious phase [22].
Mechanisms leading to neurological symptoms in 
COVID-19 might comprise hypoxia and hypercoagulability 
[12]. Moreover, the SARS-Cov-2 virus exerts its neurotrophic 
effect by interaction with ACE-2 receptor which is found in 
the brainstem among other body localisations [24, 25]. As 
shown recently, invasion of hypothalamic circuits by the 
SARS-Cov-2 virus may be responsible for mediating both 
central and peripheral nervous system symptoms [26]. The 
role of hyperactivity of the immune system with the cytokine 
storm has  also been considered [27].
Our study has several important limitations. Firstly, we 
performed additional tests to evaluate the presence of sub-
jective neurological symptoms only in a minority of patients. 
Secondly, we did not analyse the significance of paraclinical 
tests such as bloodwork or chest X-ray, which was beyond the 
scope of this report. Thirdly, due to severe neurological state, 
in some patients it was impossible to assess the presence of 
subjective neurological symptoms such as headache or de-
creased mood. Fourthly, there was a risk of selection bias due 
to the small sample of patients recruited in the Departments 
of Internal Medicine and Otorhinolaryngology. And fifthly, 
the small number of patients who died during hospitalisation 
did not allow for multivariate analysis.
Conclusions 
Our study demonstrates that neurological symptoms occur 
in most hospitalised patients with COVID-19 and that some of 
them, such as a decreased level of consciousness and delirium, 
increase the risk of in-hospital mortality. Future studies on 
larger patient populations are needed to evaluate how the 
presence of these neurological manifestations could be incor-
porated into prognostic scales for patients with COVID-19.
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